iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Core Insights - iBio, Inc. has appointed Kristi Sarno as senior vice president of business development, bringing over 25 years of experience in the life sciences industry [1][2] - Ms. Sarno's previous roles include significant positions at leading biotech companies, where she was instrumental in securing over $130 million in partnerships [2] - The company aims to expand its pipeline into obesity and metabolic therapeutics and establish collaborations with pharmaceutical companies leveraging its AI platform [3] Company Developments - Kristi Sarno's appointment is expected to enhance iBio's corporate strategy and business development activities, including transaction execution [1][3] - iBio has granted Ms. Sarno options to purchase 15,000 shares of common stock at an exercise price of $1.81 per share, with a ten-year term [3][4] - The options will vest over time, with 25% vesting on the one-year anniversary and subsequent vesting every three months, contingent on her continued employment [4] Company Overview - iBio is an AI-driven innovator focused on developing next-generation biopharmaceuticals using computational biology and 3D modeling [5] - The company's mission is to decrease drug failures, shorten development timelines, and target promising drug candidates [5]